NCT06937619

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 263 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	Risankizumab	Subcutaneous Injection

Timeline

• Start date: 2025-04-21
• Primary completion: 2025-11-10
• Completion: 2025-11-10
• First posted: 2025-04-22
• Last updated: 2025-11-17

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study